News CMS's Medicare price negotiations start round three The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.
News Eisai settles Lenvima patent dispute with Torrent Pharma A settlement between Eisai and Torrent Pharma will keep a generic version of blockbuster cancer drug Lenvima off the US market until 2030.
News MSD, Eisai abandon combination trial in liver cancer MSD and Eisai's oncology partnership has had mixed fortunes this week, with a disappointment in liver cancer and encouraging data in kidney cancer.
News Eisai moves swiftly to expand subcutaneous Leqembi label Before it has even launched, Eisai has filed to widen subcutaneous Leqembi's label to include starting as well as maintenance dosing in Alzheimer's.
News Dose-at-home Leqembi for Alzheimer's cleared in US Eisai and Biogen get FDA approval for subcutaneous Leqembi. Will it help stave off growing competition from Lilly's Kisunla in Alzheimer's treatment?
News Alzheimer's drug Leqembi launched in first EU markets Germany and Austria are the first countries in the EU to see the launch of Leqembi, Eisai and Biogen's much-delayed treatment for Alzheimer's.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
